Abstract
Fundmental and clinical evalution of new antibiotic, Coumermycin (CUM) were performed. The results obtaind are as follows:
1) In vitro antibacterial activity: Against 80 strains of coagulase positive staphylococci isolated from the otorrhoea of purulent otitis media, the MIC, measured by agar plate dilution method, distributed with two peaks, ≤0.19 (74%) and 3.13-50mcg/ml (26%). Further, the MIC of CUM was 1.56-50mcg/ml against Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, and 25-≥100mcg/ml against Pseudomonas aeruginosa. Some tendency toward Cross-resistance with CUM and NB was observed at medium concentrated of CUM.
2) Stability of Coumermycin solution: As to the stability of 10mg/ml solutions of CUM, there was no fluctuation in its color, pH and antibacterial activity within a 16-day period when the solutions were kept at 5°C and 37°C.
3) Results of clinical treatment: When CUM was administered applied locally in 35 cases of the acute or chronic purulent otitis media, it was good in 20 cases, fair in 8 cases, and poor in 6 cases. When the cases in which it was good and fair were considered together, good results were obtained in 30 cases, that is a ratio of effectiveness of 80 percent.
4) Side effect: no side effect was observed when CUM was locally used.
